Advances in pathogenic mechanisms and management of radiation-induced fibrosis

Radiation-induced fibrosis (RIF) is a severe long-term complication of the normal tissue following radiotherapy. Its prototypical characteristic is the persistent activation of myofibroblasts, resulting in proportion disorder and hyperplasia remodeling of the extracellular matrix comprising collagen...

Full description

Bibliographic Details
Main Authors: Bin Wang, Jinlong Wei, Lingbin Meng, Huanhuan Wang, Chao Qu, Xiang Chen, Ying Xin, Xin Jiang
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
ROS
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332219351832
id doaj-ef136984d0954dc3be624c69b6a8b275
record_format Article
spelling doaj-ef136984d0954dc3be624c69b6a8b2752021-05-20T07:39:16ZengElsevierBiomedicine & Pharmacotherapy0753-33222020-01-01121109560Advances in pathogenic mechanisms and management of radiation-induced fibrosisBin Wang0Jinlong Wei1Lingbin Meng2Huanhuan Wang3Chao Qu4Xiang Chen5Ying Xin6Xin Jiang7Department of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Internal Medicine, Florida Hospital, Orlando, FL 32803, USADepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, ChinaKey Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China; Corresponding author at: Key Laboratory of Pathobiology, Ministry of Education, Jilin University, 126 Xinmin Street, Changchun, 130021 China.Department of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China; Corresponding author at: Department of Radiation Oncology, the First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021 China.Radiation-induced fibrosis (RIF) is a severe long-term complication of the normal tissue following radiotherapy. Its prototypical characteristic is the persistent activation of myofibroblasts, resulting in proportion disorder and hyperplasia remodeling of the extracellular matrix comprising collagen. The continuous progress of RIF may contribute to multiple clinical manifestations such as hollow organ stenosis, impaired gaseous diffusion, and loss of tissue compliance significantly affecting the overall quality of daily life in patients with irradiated cancer. Traditionally, the potential mechanism of myofibroblast activation and differentiation has not been elucidated, and the process has been considered as static and irreversible. Recent studies have shown that RIF is a dynamic, multi-step process mediated by many regulated chemokines and cytokines. The RIF process includes release of reactive oxygen species (ROS), microvascular injury, recruitment of inflammatory cells, and activation of myofibroblasts. Numerous signaling pathways are involved in the initiation and progression of RIF, of which SMAD-regulated CTGF expression mediated by TGF-β1 is referred as the main axis. Current management strategies applied in clinical practice for patients with RIF are only supportive treatments, such as anti-inflammatory therapy using steroids; however, the efficacies achieved by these interventions are limited and unsatisfactory. Therefore, this review explores advances in RIF pathogenesis and anti-fibrosis therapy. We hope to provide clinicians with improved awareness and enormous promise in the management of RIF.http://www.sciencedirect.com/science/article/pii/S0753332219351832RadiotherapyRadiation-induced fibrosisROSTGF-β1Management strategies
collection DOAJ
language English
format Article
sources DOAJ
author Bin Wang
Jinlong Wei
Lingbin Meng
Huanhuan Wang
Chao Qu
Xiang Chen
Ying Xin
Xin Jiang
spellingShingle Bin Wang
Jinlong Wei
Lingbin Meng
Huanhuan Wang
Chao Qu
Xiang Chen
Ying Xin
Xin Jiang
Advances in pathogenic mechanisms and management of radiation-induced fibrosis
Biomedicine & Pharmacotherapy
Radiotherapy
Radiation-induced fibrosis
ROS
TGF-β1
Management strategies
author_facet Bin Wang
Jinlong Wei
Lingbin Meng
Huanhuan Wang
Chao Qu
Xiang Chen
Ying Xin
Xin Jiang
author_sort Bin Wang
title Advances in pathogenic mechanisms and management of radiation-induced fibrosis
title_short Advances in pathogenic mechanisms and management of radiation-induced fibrosis
title_full Advances in pathogenic mechanisms and management of radiation-induced fibrosis
title_fullStr Advances in pathogenic mechanisms and management of radiation-induced fibrosis
title_full_unstemmed Advances in pathogenic mechanisms and management of radiation-induced fibrosis
title_sort advances in pathogenic mechanisms and management of radiation-induced fibrosis
publisher Elsevier
series Biomedicine & Pharmacotherapy
issn 0753-3322
publishDate 2020-01-01
description Radiation-induced fibrosis (RIF) is a severe long-term complication of the normal tissue following radiotherapy. Its prototypical characteristic is the persistent activation of myofibroblasts, resulting in proportion disorder and hyperplasia remodeling of the extracellular matrix comprising collagen. The continuous progress of RIF may contribute to multiple clinical manifestations such as hollow organ stenosis, impaired gaseous diffusion, and loss of tissue compliance significantly affecting the overall quality of daily life in patients with irradiated cancer. Traditionally, the potential mechanism of myofibroblast activation and differentiation has not been elucidated, and the process has been considered as static and irreversible. Recent studies have shown that RIF is a dynamic, multi-step process mediated by many regulated chemokines and cytokines. The RIF process includes release of reactive oxygen species (ROS), microvascular injury, recruitment of inflammatory cells, and activation of myofibroblasts. Numerous signaling pathways are involved in the initiation and progression of RIF, of which SMAD-regulated CTGF expression mediated by TGF-β1 is referred as the main axis. Current management strategies applied in clinical practice for patients with RIF are only supportive treatments, such as anti-inflammatory therapy using steroids; however, the efficacies achieved by these interventions are limited and unsatisfactory. Therefore, this review explores advances in RIF pathogenesis and anti-fibrosis therapy. We hope to provide clinicians with improved awareness and enormous promise in the management of RIF.
topic Radiotherapy
Radiation-induced fibrosis
ROS
TGF-β1
Management strategies
url http://www.sciencedirect.com/science/article/pii/S0753332219351832
work_keys_str_mv AT binwang advancesinpathogenicmechanismsandmanagementofradiationinducedfibrosis
AT jinlongwei advancesinpathogenicmechanismsandmanagementofradiationinducedfibrosis
AT lingbinmeng advancesinpathogenicmechanismsandmanagementofradiationinducedfibrosis
AT huanhuanwang advancesinpathogenicmechanismsandmanagementofradiationinducedfibrosis
AT chaoqu advancesinpathogenicmechanismsandmanagementofradiationinducedfibrosis
AT xiangchen advancesinpathogenicmechanismsandmanagementofradiationinducedfibrosis
AT yingxin advancesinpathogenicmechanismsandmanagementofradiationinducedfibrosis
AT xinjiang advancesinpathogenicmechanismsandmanagementofradiationinducedfibrosis
_version_ 1721435281052139520